Nature Communications (Oct 2022)
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
- Matthew R. Chang,
- Luke Tomasovic,
- Natalia A. Kuzmina,
- Adam J. Ronk,
- Patrick O. Byrne,
- Rebecca Johnson,
- Nadia Storm,
- Eduardo Olmedillas,
- Yixuan J. Hou,
- Alexandra Schäfer,
- Sarah R. Leist,
- Longping V. Tse,
- Hanzhong Ke,
- Christian Coherd,
- Katrina Nguyen,
- Maliwan Kamkaew,
- Anna Honko,
- Quan Zhu,
- Galit Alter,
- Erica Ollmann Saphire,
- Jason S. McLellan,
- Anthony Griffiths,
- Ralph S. Baric,
- Alexander Bukreyev,
- Wayne A. Marasco
Affiliations
- Matthew R. Chang
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Luke Tomasovic
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Natalia A. Kuzmina
- Department of Pathology, University of Texas Medical Branch
- Adam J. Ronk
- Department of Pathology, University of Texas Medical Branch
- Patrick O. Byrne
- Department of Molecular Biosciences, University of Texas
- Rebecca Johnson
- Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University, School of Medicine
- Nadia Storm
- Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University, School of Medicine
- Eduardo Olmedillas
- La Jolla Institute for Immunology
- Yixuan J. Hou
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Alexandra Schäfer
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Sarah R. Leist
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Longping V. Tse
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Hanzhong Ke
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Christian Coherd
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Katrina Nguyen
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Maliwan Kamkaew
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Anna Honko
- Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University, School of Medicine
- Quan Zhu
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- Galit Alter
- Ragon Institute of MGH, MIT and Harvard
- Erica Ollmann Saphire
- La Jolla Institute for Immunology
- Jason S. McLellan
- Department of Molecular Biosciences, University of Texas
- Anthony Griffiths
- Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University, School of Medicine
- Ralph S. Baric
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Alexander Bukreyev
- Department of Pathology, University of Texas Medical Branch
- Wayne A. Marasco
- Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-022-33030-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
COVID-19 can be treated with monoclonal antibodies against SARS-CoV-2, but emerging new variants might show resistance towards existing therapy. Here authors show that anti-SARS-CoV-2 spike human single-chain antibody fragments could gain neutralizing activity against variants of concern upon engineering into a human bispecific antibody.
